Non-Hodgkin Lymphoma after Treatment with Extended Dosing Temozolomide and Radiotherapy for a Glioblastoma: A Case Report

Temozolomide (TMZ) is an alkylating agent, used for the treatment of high-grade gliomas. This case report describes the development of a non-Hodgkin lymphoma in a patient treated with extended-dose temozolomide and radiotherapy. In addition to the possible mutagenic effect of temozolomide – as descr...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Ginderachter, Laura, Cox, Tony, Drijkoningen, Ria, Achten, Ruth, Joosens, Eric, Maes, Annelies, Theunissen, Koen, Mebis, Jeroen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2013
Materias:
Published online: January, 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573799/
https://www.ncbi.nlm.nih.gov/pubmed/23466981
http://dx.doi.org/10.1159/000346614
_version_ 1782259504625221632
author Van Ginderachter, Laura
Cox, Tony
Drijkoningen, Ria
Achten, Ruth
Joosens, Eric
Maes, Annelies
Theunissen, Koen
Mebis, Jeroen
author_facet Van Ginderachter, Laura
Cox, Tony
Drijkoningen, Ria
Achten, Ruth
Joosens, Eric
Maes, Annelies
Theunissen, Koen
Mebis, Jeroen
author_sort Van Ginderachter, Laura
collection PubMed
description Temozolomide (TMZ) is an alkylating agent, used for the treatment of high-grade gliomas. This case report describes the development of a non-Hodgkin lymphoma in a patient treated with extended-dose temozolomide and radiotherapy. In addition to the possible mutagenic effect of temozolomide – as described for all alkylating agents – there might have been an immunosuppressive effect of TMZ. The pathological appearance of the lymphoma as well as the presence of a grade 3 lymphopenia early in treatment supports this hypothesis. As the use of TMZ increases, the awareness that TMZ may induce secondary malignancies should increase as well.
format Online
Article
Text
id pubmed-3573799
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-35737992013-03-05 Non-Hodgkin Lymphoma after Treatment with Extended Dosing Temozolomide and Radiotherapy for a Glioblastoma: A Case Report Van Ginderachter, Laura Cox, Tony Drijkoningen, Ria Achten, Ruth Joosens, Eric Maes, Annelies Theunissen, Koen Mebis, Jeroen Case Rep Oncol Published online: January, 2013 Temozolomide (TMZ) is an alkylating agent, used for the treatment of high-grade gliomas. This case report describes the development of a non-Hodgkin lymphoma in a patient treated with extended-dose temozolomide and radiotherapy. In addition to the possible mutagenic effect of temozolomide – as described for all alkylating agents – there might have been an immunosuppressive effect of TMZ. The pathological appearance of the lymphoma as well as the presence of a grade 3 lymphopenia early in treatment supports this hypothesis. As the use of TMZ increases, the awareness that TMZ may induce secondary malignancies should increase as well. S. Karger AG 2013-01-19 /pmc/articles/PMC3573799/ /pubmed/23466981 http://dx.doi.org/10.1159/000346614 Text en Copyright © 2013 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published online: January, 2013
Van Ginderachter, Laura
Cox, Tony
Drijkoningen, Ria
Achten, Ruth
Joosens, Eric
Maes, Annelies
Theunissen, Koen
Mebis, Jeroen
Non-Hodgkin Lymphoma after Treatment with Extended Dosing Temozolomide and Radiotherapy for a Glioblastoma: A Case Report
title Non-Hodgkin Lymphoma after Treatment with Extended Dosing Temozolomide and Radiotherapy for a Glioblastoma: A Case Report
title_full Non-Hodgkin Lymphoma after Treatment with Extended Dosing Temozolomide and Radiotherapy for a Glioblastoma: A Case Report
title_fullStr Non-Hodgkin Lymphoma after Treatment with Extended Dosing Temozolomide and Radiotherapy for a Glioblastoma: A Case Report
title_full_unstemmed Non-Hodgkin Lymphoma after Treatment with Extended Dosing Temozolomide and Radiotherapy for a Glioblastoma: A Case Report
title_short Non-Hodgkin Lymphoma after Treatment with Extended Dosing Temozolomide and Radiotherapy for a Glioblastoma: A Case Report
title_sort non-hodgkin lymphoma after treatment with extended dosing temozolomide and radiotherapy for a glioblastoma: a case report
topic Published online: January, 2013
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573799/
https://www.ncbi.nlm.nih.gov/pubmed/23466981
http://dx.doi.org/10.1159/000346614
work_keys_str_mv AT vanginderachterlaura nonhodgkinlymphomaaftertreatmentwithextendeddosingtemozolomideandradiotherapyforaglioblastomaacasereport
AT coxtony nonhodgkinlymphomaaftertreatmentwithextendeddosingtemozolomideandradiotherapyforaglioblastomaacasereport
AT drijkoningenria nonhodgkinlymphomaaftertreatmentwithextendeddosingtemozolomideandradiotherapyforaglioblastomaacasereport
AT achtenruth nonhodgkinlymphomaaftertreatmentwithextendeddosingtemozolomideandradiotherapyforaglioblastomaacasereport
AT joosenseric nonhodgkinlymphomaaftertreatmentwithextendeddosingtemozolomideandradiotherapyforaglioblastomaacasereport
AT maesannelies nonhodgkinlymphomaaftertreatmentwithextendeddosingtemozolomideandradiotherapyforaglioblastomaacasereport
AT theunissenkoen nonhodgkinlymphomaaftertreatmentwithextendeddosingtemozolomideandradiotherapyforaglioblastomaacasereport
AT mebisjeroen nonhodgkinlymphomaaftertreatmentwithextendeddosingtemozolomideandradiotherapyforaglioblastomaacasereport

Ejemplares similares